LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII (original) (raw)

• Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S et al. (2005). Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24: 4540–4548.
  Article CAS Google Scholar
• Aoki T, Hashimoto N, Matsutani M . (2007). Management of glioblastoma. Expert Opin Pharmacother 8: 3133–3146.
  Article CAS Google Scholar
• Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR et al. (1997). Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 100: 2286–2294.
  Article CAS Google Scholar
• Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S . (2006). EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene 25: 6497–6509.
  Article CAS Google Scholar
• Ferby I, Reschke M, Kudlacek O, Knyazev P, Pantè G, Amann K et al. (2006). Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12: 568–573.
  Article CAS Google Scholar
• Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C et al. (2007). A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 26: 368–381.
  Article CAS Google Scholar
• Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS . (2007). EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 7: 1408–1417.
  Article Google Scholar
• Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J et al. (2004). LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270–3281.
  Article CAS Google Scholar
• Han W, Zhang T, Yu H, Foulke JG, Tang CK . (2006). Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther 5: 1361–1368.
  Article CAS Google Scholar
• Hedman H, Nilsson J, Guo D, Henriksson R . (2002). Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 41: 352–354..
  Article CAS Google Scholar
• Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD et al. (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927–2935.
  Article CAS Google Scholar
• Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK et al. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104: 12867–12872.
  Article CAS Google Scholar
• Kirisits A, Pils D, Krainer M . (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. Int J Biochem Cell Biol 39: 2173–2182.
  Article CAS Google Scholar
• Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway III KL et al. (2004). The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050–47056.
  Article CAS Google Scholar
• Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH et al. (2004). Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10: 3216–3224.
  Article CAS Google Scholar
• Lindström AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H et al. (2008). LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18: 312–317.
  Article Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012–2024.
  Article CAS Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ . (1998). Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273: 200–206.
  Article CAS Google Scholar
• Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ . (1998). Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95: 5724–5729.
  Article CAS Google Scholar
• Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK et al. (2001). Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95: 472–479.
  Article CAS Google Scholar
• Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R . (2006). Epidermal growth factor receptor-mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12: 7261–7270.
  Article CAS Google Scholar
• Peschard P, Kozlov G, Lin T, Mirza IA, Berghuis AM, Lipkowitz S et al. (2007). Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol Cell 27: 474–485.
  Article CAS Google Scholar
• Raizer JJ . (2005). HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74: 77–86.
  Article CAS Google Scholar
• Rosell R, Taron M, Reguart N, Isla D, Moran T . (2006). Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res 12: 7222–7231.
  Article CAS Google Scholar
• Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway III KL et al. (2007). LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27: 1934–1946.
  Article CAS Google Scholar
• Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M . (2007). The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75: 770–787.
  Article CAS Google Scholar
• Sweeney C, Miller JK, Shattuck D, Carraway III KL . (2006). ErbB receptor negative regulatory mechanisms: implications in cancer. J Mammary Gland Biol Neoplasia 11: 89–99.
  Article Google Scholar
• Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S et al. (2002). Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 521: 67–71.
  Article CAS Google Scholar
• Tanemura A, Nagasawa T, Inui S, Itami S . (2005). LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423–430.
  Article CAS Google Scholar
• Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R . (2003). LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT–PCR and immunohistochemical analysis. Br J Cancer 89: 1285–1289.
  Article CAS Google Scholar
• Vassar R, Fuchs E . (1991). Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev 5: 714–727.
  Article CAS Google Scholar
• Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM et al. (2006). Mammalian target of rapamycin inhibition promotes responses to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblasma cells. Cancer Research 66: 7864–7869.
  Article CAS Google Scholar
• Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A et al. (2002). A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 21: 303–313.
  Article CAS Google Scholar
• Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG . (1990). Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247: 962–964.
  Article CAS Google Scholar